Previous experiments targeting CAFs in vivo illustrated that alpha smooth muscle actin (αSMA)-positive CAFs, primarily myofibroblastic, and Sonic Hedgehog (Shh)-positive CAFs are both tumor restrictive, while targeting FAP+ CAFs unveiled a targetable tumor-promoting CAF subpopulation and has clinical promise. This evidence concerns the gene SHH and neoplasm.